Tag: inflammasome

September 21, 2019 Off

Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases

Inflammasome Therapeutics is entitled to receive up to $160 million in milestone and gated development payments as well as tiered royalties and other milestones due on commercialization.

January 23, 2019 Off

Second Genome doses first patients in second phase testing SGM-1019

By Dino Mustafić

Second Genome has dosed first patient in a Phase 2 test of its oral, small molecule inhibitor of P2X7, called SGM-1019, for treating nonalcoholic steatohepatitis (NASH).